Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAP Cemi
NCT07433673Phase 2Recruiting
- Sponsor
- Columbia University
- Start
- Jan 2027
- Primary completion
- Jan 2032
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in biliary tract cancer (BTC), sponsored by Columbia University. Planned start Jan 2027; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07433673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07433673.